Clinical trials
Advanced Malignancies clinical trials
Below are recruiting advanced malignancies clinical trials, each written for real people, not researchers. We’re tracking 320 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07038005RecruitingPhase 1
Testing a new drug SPGL008 for advanced solid tumors
This trial tests an experimental drug called SPGL008 in people with advanced solid tumors that have spread or cannot be removed. It is a first-in-human study to learn about safety, dosing, and how the drug works.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07016490RecruitingPhase 1
Study of SSGJ-709 for advanced solid tumors
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
AdelaideAges 18 years+ - NCT06943677RecruitingPhase 1
Testing TQB3019 for advanced blood cancers
This trial tests an experimental oral capsule called TQB3019 for people with advanced blood cancers that have come back or not improved with other treatments. The goal is to see if the drug is safe and to find the right dose.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06927297RecruitingPhase 1
Safety study of a mitochondrial vaccine for advanced solid tumors
This early-phase trial tests a new type of cancer vaccine designed to help your immune system attack tumors. It is for people with advanced solid tumors who have run out of standard options.
Chengdu, SichuanAges 18–75 - NCT06915142RecruitingPhase 2
Study of HRS-7058 combined with cancer drugs for advanced solid tumors
This trial tests a new drug, HRS-7058, combined with other anti-cancer drugs for people with advanced solid tumors that cannot be surgically removed. The goal is to see if the combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06877650RecruitingPhase 1/Phase 2
Study of JMT108 for advanced solid tumors
This trial tests a new drug called JMT108 for people with advanced solid tumors that haven't responded to standard treatments. It aims to find out if the drug is safe and how well it works against cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06823609RecruitingPhase 1
Study of QLS-1304 for advanced solid tumors
This trial tests an experimental drug, QLS-1304, for people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT06764771RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
Hackensack, New JerseyAges 18 years+ - NCT06717750RecruitingPhase 1
Experimental oral drug for advanced solid tumors
This study tests an experimental oral drug (CSCJC3456) that may target certain genetic changes (FGFR) in advanced cancers. It might be an option if your cancer has not improved with standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06383871RecruitingPhase 1
A study of the new drug HRS-7058 for advanced solid tumors
This is a phase 1 study testing a new oral drug called HRS-7058 for people with advanced solid tumors that have not responded to other treatments. The main goal is to find a safe dose and see how well the drug works.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+ - NCT04165590RecruitingPhase 1/Phase 2
Plasmodium immune treatment for advanced solid tumors
This Phase 1/2 study tests an immune treatment made from Plasmodium (a malaria-related organism) in people with advanced solid cancers. It aims to see how well the treatment can control tumors and is primarily focused on early safety and whether it shows signs of benefit.
Kunming, YunnanAges 18–70 - NCT07824934RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug, HEC-921, given alone or with other cancer treatments for people with advanced solid tumors. It may be an option for those who have tried standard treatments or who have a specific marker on their tumor.
ShanghaiAges 18 years+ - NCT07810933RecruitingPhase 1/Phase 2
Study of a new ALK inhibitor for advanced cancer
This trial tests a new pill, SY-12321, for people with advanced cancer that has a specific change called ALK. The study aims to see if the drug can shrink tumors or slow their growth, and it may be an option if you've already tried other ALK-targeting treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06592417RecruitingPhase 1
Study of JSKN016 for advanced solid tumors
This trial tests a new drug called JSKN016 for people with advanced cancer that has not responded to other treatments. It focuses on certain lung and breast cancers with specific genetic markers.
Fuzhou, FujianAges 18 years+ - NCT06654440RecruitingPhase 2
Testing SHR-A2102 for advanced gynecological cancers
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06728189RecruitingPhase 1
CD70-targeted CAR-NKT cells for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
BeijingAges 18–75 - NCT06600022RecruitingPhase 1/Phase 2
Studying SCTB41 for advanced solid tumors
This trial tests a new drug called SCTB41 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it shrinks tumors.
Guangzhou, GuangdongAges 18 years+ - NCT07480733RecruitingPhase 2
Study of two drugs for advanced solid tumors
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07399769RecruitingPhase 1/Phase 2
MSLN CAR-T therapy for advanced solid tumors
This trial tests a new immune cell therapy called MSLN CAR-T for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help if your cancer has not responded to standard treatment and tests positive for a protein called mesothelin (MSLN).
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07389239RecruitingPhase 1/Phase 2
Immunotherapy for ovarian cancer and other advanced tumors
This study tests an immunotherapy treatment for people with advanced solid tumors, including ovarian cancer, sarcoma, prostate, breast, lung, and others. It is designed for tumors that show a specific marker called NY-ESO-1, and aims to see if the treatment can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+ - NCT07368478RecruitingPhase 1
Study of BC2027 for advanced solid tumors with GPC3
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
Shanghai, Shanghai, ChinaAges 18 years+ - NCT05749627Recruiting
Vaccine for advanced cancers using your tumor’s targets
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
Nanchang, JiangxiAges 18–70 - NCT07292402RecruitingPhase 1
Study of JSKN022 for advanced solid tumors
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignancies?
- Yes. Clin2 currently lists 320 recruiting advanced malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.